Evidence map›Paper›PMID 39351336›Full record

ArticleWorld journal of cardiology2024

Medical dilemma: Programmed death 1 blockade (sintilimab) therapy in patients suffering from tumours combined with psoriasis.

Di Jin, Yu-Wei Wang, Zhi-Min Lin, Chen Li, Ming Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Di JinDepartment of Rheumatology, Weifang People's Hospital, Weifang 261000, Shandong Province, China.
Yu-Wei WangDepartment of Cardiology, Yidu Central Hospital of Weifang, Weifang 261000, Shandong Province, China.
Zhi-Min LinThird Affiliated Hospital, Beijing University of Chinese Medicine, Beijing 100020, China.
Chen LiDepartment of Rheumatology, Fangshan Hospital, Beijing University of Chinese Medicine, Beijing 102400, China.
Ming LiDepartment of Rheumatology, Weifang People's Hospital, Weifang 261000, Shandong Province, China. lalwlm@aliyun.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumour immunotherapy represented by immune checkpoint inhibitors (ICIs) has greatly improved the overall prognosis of patients with malignant tumours, and is regarded as an important breakthrough in the field of medicine in recent years. ICIs have gradually become the core of tumour therapy and are increasingly used in the clinic. In order to achieve early clinical prediction and management of immune-related adverse events (irAEs), it is still necessary to perform further research on the mechanisms, risk factors, and predictors of irAE occurrence in the future. Zhou

Indexed as

Cytokine release syndromeImmune checkpoint inhibitorsImmune-related adverse eventsPsoriasisTumor immunotherapy

Identifiers

PMID39351336
PMCPMC11439104

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.